Crinetics Announces Positive Initial Findings from Ongoing O

Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was...

Related Keywords

, Corey Davis , Chas Schultz , Scott Struthers , Natalie Badillo , Crinetics Pharmaceuticals Inc , Head Of Corporate Communications , Securities Exchange , Nasdaq , Crinetics Pharmaceuticals , Significant Reductions , Both Bowel Movements , Flushing Episodes Were , Overall Pharmacokinetic Profile , Prior Studies , Topline Results Expected , Conference Call Today , Ongoing Open Label Phase , Carcinoid Syndrome , Securities Act , Securities Exchange Act , Congenital Adrenal Hyperplasia , Investor Relations , Markets ,